← 返回

胶质瘤干细胞特异性 CAR 巨噬细胞的腔内生成启动术后胶质母细胞瘤治疗的局部区域免疫

英文原题:Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy.

查看英文原题

Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy.

PubMed 2022/08/03(内容时间) Sci Transl Med Q1 · IF 15.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

多形性胶质母细胞瘤(GBM)尽管在手术减积后积极实施多模式治疗,仍然无法治愈。几乎所有GBM患者在初始切除病灶周围的狭窄边缘内复发,原因是术后残留的胶质瘤干细胞(GSCs)。追踪和根除术后残留的GSCs对于预防这种毁灭性疾病的术后复发至关重要,然而有效策略仍然难以实现。

在此,我们报告了一种可注射入腔的纳米转运体-水凝胶超结构,它在腔周围产生GSC特异性嵌合抗原受体(CAR)巨噬细胞/小胶质细胞(MΦs),以预防GBM复发。

具体而言,我们证明水凝胶中携带CAR基因的纳米转运体在腔内递送后可将GSC靶向CAR基因导入MΦ细胞核,在GBM小鼠模型中生成CAR-MΦs。这些CAR-MΦs能够寻找并吞噬GSCs,并通过在肿瘤微环境中刺激适应性抗肿瘤免疫反应来清除残留GSCs,并通过在小鼠中诱导长期抗肿瘤免疫来预防术后胶质瘤复发。在原位患者来源的胶质母细胞瘤人源化小鼠模型中,纳米转运体-水凝胶超结构与CD47抗体联合治疗增加了阳性免疫应答细胞的频率并抑制了阴性免疫调节细胞,赋予术后腔周围强大的杀肿瘤免疫,并抑制术后胶质母细胞瘤复发。

因此,我们的工作建立了一种局部区域治疗策略,用于启动癌症干细胞特异性杀肿瘤免疫,在患有复发性恶性肿瘤的患者中具有广泛的应用前景。

展开英文摘要原文

Glioblastoma multiforme (GBM) remains incurable despite aggressive implementation of multimodal treatments after surgical debulking. Almost all patients with GBM relapse within a narrow margin around the initial resected lesion due to postsurgery residual glioma stem cells (GSCs). Tracking and eradicating postsurgery residual GSCs is critical for preventing postoperative relapse of this devastating disease, yet effective strategies remain elusive.

Here, we report a cavity-injectable nanoporter-hydrogel superstructure that creates GSC-specific chimeric antigen receptor (CAR) macrophages/microglia (MΦs) surrounding the cavity to prevent GBM relapse. Specifically, we demonstrate that the CAR gene-laden nanoporter in the hydrogel can introduce GSC-targeted CAR genes into MΦ nuclei after intracavity delivery to generate CAR-MΦs in mouse models of GBM.

These CAR-MΦs were able to seek and engulf GSCs and clear residual GSCs by stimulating an adaptive antitumor immune response in the tumor microenvironment and prevented postoperative glioma relapse by inducing long-term antitumor immunity in mice.

In an orthotopic patient-derived glioblastoma humanized mouse model, the combined treatment with nanoporter-hydrogel superstructure and CD47 antibody increased the frequency of positive immune responding cells and suppressed the negative immune regulating cells, conferring a robust tumoricidal immunity surrounding the postsurgical cavity and inhibiting postoperative glioblastoma relapse.

Therefore, our work establishes a locoregional treatment strategy for priming cancer stem cell-specific tumoricidal immunity with broad application in patients suffering from recurrent malignancies.

论文信息

作者
Chen C、Jing W、Chen Y、Wang G、Abdalla M、Gao L、Han M、Shi C
单位
Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 Cultural West Road, Jinan, Shandong Province 250012, China.China
文献类型
非美国政府资助研究
期刊
Science translational medicine2022 Aug 3
原文标识
PubMed 35921473 · DOI 10.1126/scitranslmed.abn1128